Skip to content

Asset turnover at other companies

Pfizer logo
PfizerPFE
0.3×0.0×
Rogers Corporation logo
Rogers CorporationROG
0.6×0.0×
Merck & Co. logo
Merck & Co.MRK
0.5×0.0×
Gilead Sciences logo
Gilead SciencesGILD
0.5×0.0×
Nuvation Bio logo
Nuvation BioNUVB
0.3×+0.2×
Immunome logo
ImmunomeIMNM
0.0×

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.4B+546%
Enterprise value$1.42B+1,233%
P/S1,073.7×-280×

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×

Where this comes from

Calculated from Inhibrx Biosciences, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s asset turnover?
Inhibrx Biosciences, Inc. (INBX) reported asset turnover of 0× in Q4 2025.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.